Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

global access

- PMLiVE

Revolutionising healthcare: The crucial role of diagnostics in transforming the NHS

Amid the formidable challenges faced by the NHS, Onyx Health delve into the pivotal role of diagnostics in healthcare transformation, showcasing how collaboration, innovation, and patient-centric approaches are revolutionising healthcare...

Onyx Health

- PMLiVE

AbbVie’s Elahere granted full FDA approval for previously-treated ovarian cancer

The company recently gained access to the therapy through its $10.1bn acquisition of ImmunoGen

- PMLiVE

Novo Nordisk’s Awiqli receives CHMP recommendation to treat diabetes in adults

The chronic disease is estimated to affect 415 million people worldwide

- PMLiVE

Sanofi and Owkin expand AI collaboration to include drug positioning in immunology

The expansion builds on the companies’ strategic alliance previously announced in 2021

- PMLiVE

Novartis’ Fabhalta recommended by CHMP to treat rare blood disorder PNH

Paroxysmal nocturnal haemoglobinuria affects approximately ten to 20 people per million worldwide

- PMLiVE

UK survey reveals two-thirds of vitiligo patients struggle with mental health

The Vitiligo Society has launched a campaign to address the lack of awareness and understanding surrounding the condition

- PMLiVE

Women in pharma

Sanofi’s Rippon Ubhi on her new role as Country Lead for UK & Ireland

- PMLiVE

FDA approves Italfarmaco’s Duvyzat as first nonsteroidal Duchenne muscular dystrophy drug

The neuromuscular genetic disease is estimated to affect one in every 3,500 to 6,000 male births worldwide

- PMLiVE

UCB’s Bimzelx recommended by CHMP to treat hidradenitis suppurativa in adults

The inflammatory skin disease affects an estimated 1% of the population in most studied countries

- PMLiVE

AbbVie and Parvus Therapeutics collaborate to develop treatments for inflammatory bowel disease

Both companies will utilise Parvus’ Navacim Treg immune tolerisation platform technology

- PMLiVE

AstraZeneca’s Tagrisso combination shows promising overall survival trend in phase 3 lung cancer study

An estimated 2.4 million people globally are diagnosed with lung cancer every year

- PMLiVE

New blood test could identify individuals at highest risk of developing heart failure

Measuring NPY alongside BNP could help healthcare professionals improve diagnosis for heart patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links